Abiraterone Acetate: In Metastatic Castration-Resistant Prostate Cancer

By Yang Lily P.H.  

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 2067-2077

Adis International

Access to resources Recommend Favorite

Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer

By Scott Lesley J.   Yang Lily P.H.   Lyseng-Williamson Katherine A.  

Drugs & Aging, Vol. 29, Iss. 3, 2012-03 ,pp. : 243-248

Adis International

Access to resources Recommend Favorite

A Rapid, Direct and Validated HPLC- Fluorescence Method for the Quantification of Abiraterone and Abiraterone Acetate in Urine and Serum Samples from Patients with Castration- Resistant Prostate Cancer

By  

Current Pharmaceutical Analysis, Vol. 14, Iss. 3, 2018-04 ,pp. : 233-238

Bentham Science Publishers

Access to resources Recommend Favorite

Prostate cancer: abiraterone acetate beats cabazitaxel

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 667, 2012-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment

By Badrising Sushil   van der Noort Vincent   van Oort Inge M.   van den Berg H. Pieter   Los Maartje   Hamberg Paul   Coenen Jules L.   van den Eertwegh Alfons J. M.   de Jong Igle J.   Kerver Emile D.   van Tinteren Harm   Bergman Andries M.  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

Blackwell Publishing

Access to resources Recommend Favorite